Yondelis I.V. infusion 0.25 mg/1 mg special drug use-results survey (all-case surveillance)

Trial Profile

Yondelis I.V. infusion 0.25 mg/1 mg special drug use-results survey (all-case surveillance)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 03 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 16 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top